DeepMed Research

Takeda Pharmaceutical Company Ltd

🇯🇵Japan

Country: 🇯🇵Japan

Ownership: -

Established: 1925-01-01

Employees: -

Market Cap: $47.5B

Website: http://www.takeda.co.jp/

Clinical Trials

A Phase 1 Study Evaluating the Safety, Tolerability and Pharmacokinetics of Trebananib (AMG 386 ) in Adult Japanese Participants With Advanced Solid Tumors

Phase 1

Completed

Conditions: Neoplasms, Advanced Solid

Interventions: Drug: Trebananib 10 mg/kg
Drug: Trebananib 30 mg/kg
Drug: Trebananib 3 mg/kg

First Posted Date: 2015-08-17

Last Posted Date: 2015-09-22

Lead Sponsor: Takeda

Target Recruit Count: 18

Registration Number: NCT02525536

Azilsartan Medoxomil in the Treatment of Essential Hypertension and Type 2 Diabetes in Asia

Phase 4

Completed

Conditions: Type 2 Diabetes Mellitus
Essential Hypertension

Interventions: Drug: Azilsartan Medoxomil

First Posted Date: 2015-08-07

Last Posted Date: 2019-03-01

Lead Sponsor: Takeda

Target Recruit Count: 380

Registration Number: NCT02517866

A Phase 3, Randomized, Double-blind, Parallel-group, Comparative Study and a Phase 3, Multicenter, Open-label, Long-term Study of SYR-472 (25 mg) in Patients With Type 2 Diabetes Mellitus Complicated by Severe Renal Impairment or End-stage Renal Disease

Phase 3

Completed

Conditions: Type 2 Diabetes Mellitus

Interventions: Drug: Trelagliptin 25 mg
Drug: Placebo

First Posted Date: 2015-07-30

Last Posted Date: 2023-12-12

Lead Sponsor: Takeda

Target Recruit Count: 107

Registration Number: NCT02512068

Phase 1 Bioavailability Study of SYR-322MET

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Drug: Alogliptin
Drug: Metformin Hydrochloride
Drug: SYR-322MET

First Posted Date: 2015-07-24

Last Posted Date: 2016-10-05

Lead Sponsor: Takeda

Target Recruit Count: 24

Registration Number: NCT02508168

Phase 1, Febuxostat XR Relative Bioavailability Study

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Drug: Febuxostat XR 80 mg Capsule F1
Drug: Febuxostat XR 80 mg Capsule F2
Drug: Febuxostat XR 80 mg Capsule F3
Drug: Febuxostat XR 80 mg Capsule F4

First Posted Date: 2015-07-21

Last Posted Date: 2017-01-19

Lead Sponsor: Takeda

Target Recruit Count: 78

Registration Number: NCT02504320

An Efficacy and Safety Study of Vedolizumab Intravenous (IV) Compared to Adalimumab Subcutaneous (SC) in Participants With Ulcerative Colitis

Phase 3

Completed

Conditions: Colitis, Ulcerative

Interventions: Drug: Vedolizumab
Drug: Adalimumab
Drug: Vedolizumab placebo
Drug: Adalimumab placebo

First Posted Date: 2015-07-14

Last Posted Date: 2020-01-28

Lead Sponsor: Takeda

Target Recruit Count: 771

Registration Number: NCT02497469

Locations: 🇺🇸
Chevy Chase Clinical Research, Chevy Chase, Maryland, United States
🇺🇸
Texas Digestive Disease Consultants - Dallas, Dallas, Texas, United States
🇺🇸
Rush University Medical Center, Chicago, Illinois, United States

and more 326 locations

A Phase 1 Positron Emission Tomography Study to Measure Cholesterol 24S-Hydroxylase Target Occupancy of TAK-935

Phase 1

Completed

Conditions: Epilepsy, Molecular Mechanisms of Pharmalogical Action, Protective Agents

Interventions: Drug: TAK-935
Drug: [18F]MNI-792 (tracer)

First Posted Date: 2015-07-14

Last Posted Date: 2017-04-11

Lead Sponsor: Takeda

Target Recruit Count: 11

Registration Number: NCT02497235

A Study to Assess the Relative Bioavailability and to Assess the Effect of Food on the Bioavailability of a TAK-648 Tablet in Healthy Participants

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Drug: TAK-648 Tablet
Drug: TAK-648 Oral Solution

First Posted Date: 2015-06-24

Last Posted Date: 2016-08-31

Lead Sponsor: Takeda

Target Recruit Count: 24

Registration Number: NCT02480439

Azilsartan Medoxomil (TAK-491) Compared to Valsartan in Chinese Participants With Hypertension

Phase 3

Completed

Conditions: Essential Hypertension

Interventions: Drug: Azilsartan medoxomil
Drug: Valsartan
Drug: Azilsartan medoxomil Placebo
Drug: Valsartan Placebo

First Posted Date: 2015-06-24

Last Posted Date: 2019-03-05

Lead Sponsor: Takeda

Target Recruit Count: 612

Registration Number: NCT02480764

Locations: 🇨🇳
Beijing Chao Yang Hospital, Beijing, Beijing, China
🇨🇳
Fujian Medical University Union Hospital, Fuzhou, Fujian, China
🇨🇳
Beijing Anzhen Hospital, Beijing, Beijing, China

and more 27 locations

A Phase 2 Efficacy and Safety Study of TAK-063 in Participants With an Acute Exacerbation of Schizophrenia

Phase 2

Completed

Conditions: Schizophrenia

Interventions: Drug: Placebo
Drug: TAK-063 20 mg

First Posted Date: 2015-06-22

Last Posted Date: 2017-09-29

Lead Sponsor: Takeda

Target Recruit Count: 164

Registration Number: NCT02477020

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy